Treatment of idiopathic pulmonary fibrosis with losartan: A pilot project

Lung

Volumn 190, Issue 5, 2012, Pages 523-527

  Couluris, Marisa ^a   Kinder, Brent W ^b   Xu, Ping ^a   Gross King, Margaret ^a   Krischer, Jeffrey ^a   Panos, Ralph J ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin receptor blocker; Dyspnea; Forced vital capacity; Pulmonary fibrosis; Six minute walk test

Indexed keywords

CARBON MONOXIDE; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; WALKING;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DYSPNEA; EXERCISE TEST; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LOSARTAN; MALE; MIDDLE AGED; PILOT PROJECTS; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 84866732337     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-012-9410-z     Document Type: Article

References (34)

1. ATS/ERS (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161(2 Pt 1):646-664
2. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP (1998) Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157:199-203
3. King TE Jr, Tooze JA, Schwarz MI (2001) Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164:1171-1181
4. Marshall RP, Gohlke P, Chambers RC et al (2004) Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 286:L156-L164
5. Papp M, Li X, Zhuang J et al (2002) Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol 282:L714-L718
6. Yao HW, Zhu JP, Zhao MH, Lu Y (2006) Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. Respiration 73(2): 236-242
7. Molteni A, Moulder JE, Cohen EF et al (2000) Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 76(4):523-532
8. Li X, Rayford H, Uhal BD (2003) Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol 163:2523-2530
9. Wei H, Li D, Lu H et al (2000) Effects of angiotensin II receptor blockade on hepatic fibrosis in rats. Zhonghua Gan Zang Bing Za Zhi 8(5):302-304
10. Wei HS, Li DG, Lu HM et al (2000) Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). World J Gastroenterol 6(4):540-545
11. Wei YH, Jun L, Qiang CJ (2004) Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats. Dig Dis Sci 49(10):1589-1594
12. Molina-Molina M, Serrano-Mollar A, Bulbena O et al (2006) Losartan attenuates bleomycin-induced lung fibrosis by increasing prostaglandin-E2 synthesis. Thorax 61:604-610
13. Park DH, Baik SK, Choi YH et al (2007) Inhibitory effect of angiotensin blockade on hepatic fibrosis in common bile ductligated rats. Korean J Hepatol 13(1):61-69
14. Croquet V, Moal F, Veal N et al (2002) Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 37(6):773-780
15. Kellner D, Chen J, Richardson I et al (2006) Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. J Urol 172(2):806-812
16. Moulder JE, Fish BL, Cohen EP (1998) Angiotensin II receptor antagonist in the treatment and prevention of radiation nephropathy. Int J Radiat Biol 73(4):415-421
17. Liang X, Xie X, Yang T, Sun M, Zhao S (2002) Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. Chin Med J (Engl) 115(9):1287-1291
18. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian AJ (2001) Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103:789-791
19. Sookoian S, Fernández MA, Castaño G (2005) Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. World J Gastroenterol 11(48): 7560-7563
20. Shibasaki Y, Nishiue T, Masaki H, Tamura K, Matsumoto N, Mori Y et al (2005) Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with endstage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens Res 28:787-795
21. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 106(25):12-17
22. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K (2004) Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40(5): 1222-1225
23. Enright PL, Beck KC, Sherrill DL (2004) Repeatability of spirometry in 18,000 adult patients. Am J Respir Crit Care Med 169:235-238
24. Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown K (2010) The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 65:173-177
25. Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861-869
26. López G, Querejeta R, Larman M, Díez J (2005) Myocardial COX-2 overexpression and fibrosis in hypertensive heart disease. Am J Hypertens 18(5 Pt 2):A223-A233
27. Raghu G, Brown KK, Bradford WZ et al (2004) A placebocontrolled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 250(2):125-133
28. Raghu G, Brown KK, Costabel U et al (2008) Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 178(9):948-955
29. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR (2010) Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 181(6):604-610
30. King TE Jr, Behr J, Brown KK et al (2008) BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177(1):75-81
31. King TE Jr, Brown KK, Raghu G, duBois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J (2011) BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184:92-99
32. Raghu G, Johnson WC, Lockhart D, Mageto Y (1999) Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open label phase II study. Am J Respir Crit Care Med 159:1061-1069
33. Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760-1769
34. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788-824